Syros Pharmaceuticals Inc. (NASDAQ: SYRS) kicked off on Monday, up 14.29% from the previous trading day, before settling in for the closing price of $1.96. Over the past 52 weeks, SYRS has traded in a range of $1.43-$8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 128.79% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 64.31%. With a float of $19.76 million, this company’s outstanding shares have now reached $26.45 million.
In an organization with 68 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 62.39%, operating margin of -2892.43%, and the pretax margin is -3171.7%.
Syros Pharmaceuticals Inc. (SYRS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syros Pharmaceuticals Inc. is 26.31%, while institutional ownership is 56.13%. The most recent insider transaction that took place on Sep 11 ’24, was worth 85,420. In this transaction President & CEO of this company bought 50,000 shares at a rate of $1.71, taking the stock ownership to the 122,504 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Financial Officer bought 45,344 for $1.68, making the entire transaction worth $76,006. This insider now owns 124,552 shares in total.
Syros Pharmaceuticals Inc. (SYRS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 64.31% per share during the next fiscal year.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Trading Performance Indicators
Take a look at Syros Pharmaceuticals Inc.’s (SYRS) current performance indicators. Last quarter, stock had a quick ratio of 3.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.30, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.71 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc. (SYRS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.5 million. That was better than the volume of 0.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.95%. Additionally, its Average True Range was 0.15.
During the past 100 days, Syros Pharmaceuticals Inc.’s (SYRS) raw stochastic average was set at 14.73%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.30% in the past 14 days, which was lower than the 170.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8800, while its 200-day Moving Average is $4.9500. However, in the short run, Syros Pharmaceuticals Inc.’s stock first resistance to watch stands at $2.3600. Second resistance stands at $2.4700. The third major resistance level sits at $2.7100. If the price goes on to break the first support level at $2.0100, it is likely to go to the next support level at $1.7700. The third support level lies at $1.6600 if the price breaches the second support level.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Key Stats
The company with the Market Capitalisation of 60.05 million has total of 26,728K Shares Outstanding. Its annual sales at the moment are 9,940 K in contrast with the sum of -164,570 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -3,710 K.
